Retrospective analysis of anti-inflammatory therapies during the first wave of COVID-19 at a community hospital

Table 2 Pharmacologic and therapeutic interventions in coronavirus disease 2019 intensive care unit patients, n (%)

	Non-survivor (n = 167)	Survivor (n = 94)	P value	OR	95%CI
GC (all patients)1	99 (59)	68 (72)	0.035	0.55	0.32-0.96
Vasopressors	124 (74)	35 (37)	< 0.001	4.8	2.8-8.4
IV Ascorbic acid	100 (59)	54 (57)	0.7	1.1	0.66-1.84
Hydroxychloroquine	128 (78)	69 (75)	0.57	1.2	0.65-2.1
Azithromycin	65 (40)	25 (26)	0.06	1.69	0.97-2.9
Heparin therapeutic dose	80 (48)	51 (54)	0.32	0.77	0.46-1.3
Heparin prophylaxis dose	58 (35)	32 (34)	0.91	1.03	0.6-1.75
Convalescent plasma	44 (26)	27 (29)	0.68	0.88	0.5-1.56
Remdesivir	6 (3)	0 (0)
Prone positioning	52 (31)	32 (35)	0.91	1.03	0.6-1.75
Tocilizumab	20 (12)	8 (8.5)	0.55	1.28	0.56-2.9
GC only	44 (26)	29 (30)	0.47	0.8	0.48-1.4
GC + tocilizumab	55 (32)	39 (40)	0.16	0.68	0.4-1.15

¹Treatment stratified as total patients receiving glucocorticoid (GC) therapy (GC alone and GC + tocilizumab).

GC: Glucocorticoid; OR: Odds ratio; CI: Confidence interval; IV: Intravenous.